{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T01:17:13Z","timestamp":1711588633912},"reference-count":11,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,27]]},"DOI":"10.7759\/cureus.57040","type":"journal-article","created":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T14:29:01Z","timestamp":1711549741000},"source":"Crossref","is-referenced-by-count":0,"title":["Vintage Victory: Warfarin Versus Apixaban in the Antiphospholipid Arena"],"prefix":"10.7759","author":[{"given":"Michael","family":"Sabina","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zein","family":"Barakat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernardo","family":"Costa Guerra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Lurie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zoya","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1112830","article-title":"The pathogenesis of the antiphospholipid syndrome","volume":"368","author":"Giannakopoulos B","year":"2013","unstructured":"Giannakopoulos B, Krilis SA. The pathogenesis of the antiphospholipid syndrome. N Engl J Med. 2013, 368:1033-44. 10.1056\/NEJMra1112830","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60709-X","article-title":"Antiphospholipid syndrome","volume":"376","author":"Ruiz-Irastorza G","year":"2010","unstructured":"Ruiz-Irastorza G, Crowther M, Branch W, et al.. Antiphospholipid syndrome. Lancet. 2010, 376:1498-509. 10.1016\/S0140-6736(10)60709-X","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.7326\/M19-0291","article-title":"Rivaroxaban versus vitamin K antagonist in antiphospholipid syndrome: a randomized noninferiority trial","volume":"171","author":"Ordi-Ros J","year":"2019","unstructured":"Ordi-Ros J, S\u00e1ez-Comet L, P\u00e9rez-Conesa M, et al.. Rivaroxaban versus vitamin K antagonist in antiphospholipid syndrome: a randomized noninferiority trial. Ann Intern Med. 2019, 171:685-94. 10.7326\/M19-0291","journal-title":"Ann Intern Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.715878","article-title":"Use of direct oral anticoagulants in patients with antiphospholipid syndrome: a systematic review and comparison of the international guidelines","volume":"8","author":"Pastori D","year":"2021","unstructured":"Pastori D, Menichelli D, Cammisotto V, Pignatelli P. Use of direct oral anticoagulants in patients with antiphospholipid syndrome: a systematic review and comparison of the international guidelines. Front Cardiovasc Med. 2021, 8:715878. 10.3389\/fcvm.2021.715878","journal-title":"Front Cardiovasc Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14935","article-title":"Use of direct oral anticoagulants in patients with thrombotic antiphospholipid syndrome: guidance from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis","volume":"18","author":"Zuily S","year":"2020","unstructured":"Zuily S, Cohen H, Isenberg D, et al.. Use of direct oral anticoagulants in patients with thrombotic antiphospholipid syndrome: guidance from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost. 2020, 18:2126-37. 10.1111\/jth.14935","journal-title":"J Thromb Haemost"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(16)30079-5","article-title":"Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2\/3, non-inferiority trial","volume":"3","author":"Cohen H","year":"2016","unstructured":"Cohen H, Hunt BJ, Efthymiou M, et al.. Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2\/3, non-inferiority trial. Lancet Haematol. 2016, 3:e426-36. 10.1016\/S2352-3026(16)30079-5","journal-title":"Lancet Haematol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-016-0623-7","article-title":"Direct oral anticoagulants use in antiphospholipid syndrome: are these drugs an effective and safe alternative to warfarin? A systematic review of the literature","volume":"18","author":"Dufrost V","year":"2016","unstructured":"Dufrost V, Risse J, Zuily S, Wahl D. Direct oral anticoagulants use in antiphospholipid syndrome: are these drugs an effective and safe alternative to warfarin? A systematic review of the literature. Curr Rheumatol Rep. 2016, 18:74. 10.1007\/s11926-016-0623-7","journal-title":"Curr Rheumatol Rep"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-04-848333","article-title":"Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome","volume":"132","author":"Pengo V","year":"2018","unstructured":"Pengo V, Denas G, Zoppellaro G, et al.. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood. 2018, 132:1365-71. 10.1182\/blood-2018-04-848333","journal-title":"Blood"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-021-02587-0","article-title":"Direct oral anticoagulants versus warfarin in patients with single or double antibody-positive antiphospholipid syndrome","volume":"54","author":"Williams B","year":"2022","unstructured":"Williams B, Saseen JJ, Trujillo T, Palkimas S. Direct oral anticoagulants versus warfarin in patients with single or double antibody-positive antiphospholipid syndrome. J Thromb Thrombolysis. 2022, 54:67-73. 10.1007\/s11239-021-02587-0","journal-title":"J Thromb Thrombolysis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13770","article-title":"Direct oral anticoagulants versus warfarin in patients with single antibody-positive anti-phospholipid syndrome","volume":"109","author":"Liu A","year":"2022","unstructured":"Liu A, Rupani KV, Naymagon L. Direct oral anticoagulants versus warfarin in patients with single antibody-positive anti-phospholipid syndrome. Eur J Haematol. 2022, 109:69-74. 10.1111\/ejh.13770","journal-title":"Eur J Haematol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005808","article-title":"Apixaban compared with warfarin to prevent thrombosis in thrombotic antiphospholipid syndrome: a randomized trial","volume":"6","author":"Woller SC","year":"2022","unstructured":"Woller SC, Stevens SM, Kaplan D, et al.. Apixaban compared with warfarin to prevent thrombosis in thrombotic antiphospholipid syndrome: a randomized trial. Blood Adv. 2022, 6:1661-70. 10.1182\/bloodadvances.2021005808","journal-title":"Blood Adv"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/236111-vintage-victory-warfarin-versus-apixaban-in-the-antiphospholipid-arena","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T14:29:04Z","timestamp":1711549744000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/236111-vintage-victory-warfarin-versus-apixaban-in-the-antiphospholipid-arena"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,27]]},"references-count":11,"URL":"https:\/\/doi.org\/10.7759\/cureus.57040","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3,27]]}}}